Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.42 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12884269 | 0.79 | GRM5 (0.60) | GRM5ALOX5CYP2A6ADRB2ASIC3 | |
| SCHEMBL12884270 | 0.77 | GRM5 (0.58) | GRM5ALOX5CYP2A6ADRB2ASIC3 | |
| SCHEMBL12884267 | 0.76 | GRM5 (0.57) | GRM5ALOX5CYP2A6ADRB2ASIC3 | |
| SCHEMBL5515924 | 0.75 | CYP2A6 (0.49) | GRM5CYP2A6PTAFR | |
| SCHEMBL9203796 | 0.74 | GRM5 (0.59) | GRM5ALOX5CYP2A6ADRB2ASIC3 | |
| SCHEMBL12278317 | 0.73 | GRM5 (0.35) | GRM5 | |
| SCHEMBL12277747 | 0.73 | GRM5 (0.35) | GRM5 | |
| SCHEMBL12279037 | 0.73 | GRM5 (0.33) | GRM5PTAFR | |
| SCHEMBL17426163 | 0.73 | GRM5 (0.33) | GRM5PTAFR | |
| SCHEMBL5196102 | 0.72 | ALOX5 (0.60) | GRM5ALOX5CYP2A6MGLLBCL2L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2020-05-21 | — | — | US | disclosed |
| EP-1740579-B1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBVIE INC (US) | 2015-08-19 | — | — | EP | disclosed |
| WO-2010146125-A1 | ESTER DERIVATIVES AS COMPETITIVE INHIBITORS OF TYPE II DEHYDROQUINASE ENZYME | UNIVERSIDADE DE SANTIAGO DE COMPOSTELA (ES) | 2010-12-23 | — | — | WO | disclosed |
| US-7468371-B2 | Tricyclic pyrazole kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1740579-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | Abbott Laboratories (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | ABBVIE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005095387-A1 | TRICYCLIC PYRAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-0538310-B1 | ETHYNYLBENZOTHIOPHENE PESTICIDES | FMC CORP (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0538310-A4 | ETHYNYLBENZOTHIOPHENE PESTICIDES | — | 1993-07-14 | — | — | EP | disclosed |
| EP-0538310-A1 | ETHYNYLBENZOTHIOPHENE PESTICIDES. | FMC CORP (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1992000672-A1 | ETHYNYLBENZOTHIOPHENE PESTICIDES | FMC CORPORATION (US) | 1992-01-23 | — | — | WO | disclosed |
| US-5073564-A | Photoactivated insecticides | FMC CORPORATION (US) | 1991-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157076-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | GRM5 3153/4885ALOX5 2259/4885CYP2A6 2713/4885 |
| US-20060014816-A1 | Tricyclic pyrazole kinase inhibitors | PRKDC, PRKACA, PIK3C3 | GRM5 1797/4885ALOX5 3815/4885CYP2A6 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.